This is the authors' abstract. We don't add key points for this paper.
Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lorusso et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: